logo

For the Inventor, By the Inventor

Fremont, CA, United States of America

Lewis H Lambert, Jr

USPTO Granted Patents = 16

Average Co-Inventor Count = 1.3

ph-index = 7

Forward Citations = 149(Granted Patents)


Company Filing History:

goldMedal16 out of 142 
 
Xoma Corporation
 patents

Years Active: 1996-2005

Loading Chart...
16 patents (USPTO):Explore Patents
1. 6849598 - Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products (2005-02-01),
2. 6620785 - Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products (2003-09-16),
3. 6583116 - Anti-chlamydial methods and materials (2003-06-24),
4. 6440936 - Anti-protozoan methods and materials (2002-08-27),
5. 6271203 - Anti-protozoan methods and materials (2001-08-07),
6. 6214789 - Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products (2001-04-10),
7. 6162788 - Uses of BPI protein products (2000-12-19),
8. 6140306 - Method of treating gram-negative bacterial infection by administration (2000-10-31),
9. 6054431 - Anti-gram-positive bacterial methods and materials (2000-04-25),
10. 6013629 - Anti-protozoan methods and materials (2000-01-11),
11. 5912228 - Therapeutic compositions comprising bactericidal/permeability-increasing (1999-06-15),
12. 5888973 - Anti-chlamydial uses of BPI protein products (1999-03-30),
13. 5783561 - Anti-gram-positive bacterial methods and materials (1998-07-21),
14. 5646114 - Anti-protozoan methods (1997-07-08),
15. 5578572 - Anti-gram-positive bacterial methods and materials (1996-11-26),

Title: Innovations and Contributions of Lewis H. Lambert, Jr.

Introduction

Lewis H. Lambert, Jr. is a prominent inventor based in Fremont, California, recognized for his significant contributions to the field of therapeutic compositions. With a commendable portfolio of 16 patents, Lambert has established himself as an innovator dedicated to enhancing medical treatments through the use of novel bactericidal proteins.

Latest Patents

Among Lambert's most recent patents are groundbreaking innovations in therapeutic compositions that utilize bactericidal/permeability-increasing (BPI) protein products. One notable patent focuses on improving these compositions to exhibit enhanced antimicrobial activity. This involves using a combination of BPI protein products and a bactericidal-activity enhancing polyoxyethylene block copolymer surfactant, also known as a poloxamer surfactant. Additionally, the formulations can be employed alongside antibiotics to treat bacterial infections effectively. Another significant patent addresses the treatment of mycobacterial diseases, outlining methods for administering BPI protein products, either alone or with anti-mycobacterial antibiotics, to combat infections caused by Mycobacteria.

Career Highlights

Lewis H. Lambert, Jr. is affiliated with Xoma Corporation, a company dedicated to developing innovative therapeutics. Through his work at Xoma, Lambert has committed himself to research that ultimately improves patient outcomes and expands the capabilities of existing treatments in infectious diseases.

Collaborations

Throughout his career, Lambert has collaborated with notable colleagues, including Roger G. Little, II and Arnold H. Horwitz. These partnerships have likely contributed to the innovative approaches and successful outcomes in the projects undertaken in the realm of therapeutic developments.

Conclusion

Lewis H. Lambert, Jr.'s inventive spirit and dedication to creating advanced therapeutic solutions underline his importance in the field of healthcare. Through his patents and collaborations, he continues to influence the medical landscape, showcasing the essence of innovation in addressing complex health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…